Skip to main content
SpringerLink
Log in

Intermittent Chemotherapy with Docetaxel for Metastatic Castration-Resistant Prostate Cancer

  • Chapter
  • First Online:
Book cover Hormone Therapy and Castration Resistance of Prostate Cancer

  • 577 Accesses

Abstract

The optimal schedule of docetaxel chemotherapy for castration-resistant prostate cancer is unknown, although continuous administration is accepted as the standard. However, several disadvantages, including side effects, costs, and development of resistant clones, need to be considered during continuous administration of docetaxel. Intermittent docetaxel therapy represents an appealing option to address these issues. Previous studies have reported that intermittent docetaxel therapy is associated with favorable outcomes, with successful chemotherapy holidays and maintained Quality of Life (QOL). However, limitations of these studies include a wide variation in study design and schedule and a lack of randomized trials comprising a large number of patients allowing comparison of outcomes with continuous administration. This chapter summarizes current data on intermittent docetaxel therapy in androgen-independent and castration-resistant prostate cancer from previous literature and examines future directions regarding the use of this strategy as a therapeutic option for advanced prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.

    Article  CAS  Google Scholar 

  2. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20.

    Article  CAS  Google Scholar 

  3. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242–5.

    Article  CAS  Google Scholar 

  4. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–46.

    Article  CAS  Google Scholar 

  5. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–77.

    Article  CAS  Google Scholar 

  6. Klil-Drori AJ, Azoulay L, Pollak MN. Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing? Nat Rev Clin Oncol. 2017;14(2):85–99.

    Article  CAS  Google Scholar 

  7. Miyake H, Sakai I, Terakawa T, Harada K, Fujisawa M. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer. Urol Oncol. 2013;31(6):733–8.

    Article  CAS  Google Scholar 

  8. Gyawali B, Koomulli-Parambil S, Iddawela M. Continuous versus intermittent docetaxel for metastatic castration resistant prostate cancer. Crit Rev Oncol Hematol. 2016;102:118–24.

    Article  Google Scholar 

  9. De Souza R, Zahedi P, Moriyama EH, Allen CJ, Wilson BC, Piquette-Miller M. Continuous docetaxel chemotherapy improves therapeutic efficacy in murine models of ovarian cancer. Mol Cancer Ther. 2010;9(6):1820–30.

    Google Scholar 

  10. Chen CS, Doloff JC, Waxman DJ. Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression. Neoplasia. 2014;16(1):84–96.

    Article  CAS  Google Scholar 

  11. Muss HB, Case LD, Richards F 2nd, White DR, Cooper MR, Cruz JM, et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The piedmont oncology association. N Engl J Med. 1991;325(19):1342–8.

    Article  CAS  Google Scholar 

  12. Maughan TS, James RD, Kerr DJ, Ledermann JA, Seymour MT, Topham C, et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet. 2003;361(9356):457–64.

    Article  CAS  Google Scholar 

  13. Gerber DE, Schiller JH. Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. J Clin Oncol. 2013;31(8):1009–20.

    Article  CAS  Google Scholar 

  14. Magnan S, Zarychanski R, Pilote L, Bernier L, Shemilt M, Vigneault E, et al. Intermittent vs continuous androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. JAMA Oncol. 2015;1(9):1261–9.

    Article  Google Scholar 

  15. Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM. Intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer. 2003;89(6):968–70.

    Article  CAS  Google Scholar 

  16. Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM. Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer. 2004;91(8):1425–7.

    Article  CAS  Google Scholar 

  17. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, et al. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer. 2008;112(2):326–30.

    Article  CAS  Google Scholar 

  18. Soga N, Kato M, Nishikawa K, Hasegawa Y, Yamada Y, Kise H, et al. Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients. Int J Clin Oncol. 2009;14(2):130–5.

    Article  CAS  Google Scholar 

  19. Mountzios I, Bournakis E, Efstathiou E, Varkaris A, Wen S, Chrisofos M, et al. Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer. Urology. 2011;77(3):682–7.

    Article  Google Scholar 

  20. Narita S, Tsuchiya N, Yuasa T, Maita S, Obara T, Numakura K, et al. Outcome, clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel, estramustine phosphate and carboplatin for castration-resistant prostate cancer. Int J Clin Oncol. 2012;17(3):204–11.

    Article  CAS  Google Scholar 

  21. Li YF, Zhang SF, Zhang TT, Li L, Gan W, Jia HT, et al. Intermittent tri-weekly docetaxel plus bicalutamide in patients with castration-resistant prostate cancer: a single-arm prospective study using a historical control for comparison. Asian J Androl. 2013;15(6):773–9.

    Article  Google Scholar 

  22. Aggarwal RR, Beer TM, Weinberg VK, Higano C, Taplin ME, Ryan CJ, et al. Intermittent chemotherapy as a platform for testing novel agents in patients with metastatic castration-resistant prostate cancer: a department of defense prostate cancer clinical trials consortium randomized phase II trial of intermittent docetaxel with prednisone with or without maintenance GM-CSF. Clin Genitourin Cancer. 2015;13(3):e191–8.

    Article  Google Scholar 

  23. Caffo O, Lo Re G, Sava T, Buti S, Sacco C, Basso U, et al. Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients. Future Oncol. 2015;11(6):965–73.

    Article  CAS  Google Scholar 

  24. Kume H, Kawai T, Nagata M, Azuma T, Miyazaki H, Suzuki M, et al. Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer. Mol Clin Oncol. 2015;3(2):303–7.

    Article  Google Scholar 

  25. Narita S, Koie T, Yamada S, Orikasa K, Matsuo S, Aoki H, et al. A prospective multicenter study of intermittent chemotherapy with docetaxel and prednisolone for castration-resistant prostate cancer. Jpn J Clin Oncol. 2016;46(6):547–53.

    Article  Google Scholar 

  26. Huang M, Narita S, Numakura K, Tsuruta H, Saito M, Inoue T, et al. A high-fat diet enhances proliferation of prostate cancer cells and activates MCP-1/CCR2 signaling. Prostate. 2012;72(16):1779–88.

    Article  CAS  Google Scholar 

  27. Abdollah F, Sood A, Sammon JD, Hsu L, Beyer B, Moschini M, et al. Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients. Eur Urol. 2015;68(3):497–505.

    Article  Google Scholar 

  28. Matsuyama H, Shimabukuro T, Hara I, Kohjimoto Y, Suzuki K, Koike H, et al. Combination of hemoglobin, alkaline phosphatase, and age predicts optimal docetaxel regimen for patients with castration-resistant prostate cancer. Int J Clin Oncol. 2014;19(5):946–54.

    Article  CAS  Google Scholar 

  29. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.

    Article  CAS  Google Scholar 

  30. Rexer H. AUO study in hormone-refractory prostate cancer. Phase III study on treatment of hormone-refractory prostate cancer (HRPC) with docetaxel: continuous treatment vs. intermittent repetition of treatment after renewed progression—PRINCE. Urologe A. 2006;45(7):872.

    Article  CAS  Google Scholar 

  31. Kapoor A, Hotte SJ. Chemotherapy research for metastatic prostate cancer. Can Urol Assoc J. 2016;10(7-8Suppl3):S140–3.

    Article  Google Scholar 

  32. Cash H, Steiner U, Heidenreich A. PRINCE: a phase 3 study comparing intermittent docetaxel therapy vs. continuous docetaxel therapy in patients with castration-resistant prostate cancer. J Clin Oncol. 2016;34:Abstr 5005.

    Google Scholar 

  33. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–54.

    Article  Google Scholar 

  34. Nozawa M, Mukai H, Takahashi S, Uemura H, Kosaka T, Onozawa Y, et al. Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer. Int J Clin Oncol. 2015;20(5):1026–34.

    Article  CAS  Google Scholar 

  35. Omlin A, Sartor O, Rothermundt C, Cathomas R, De Bono JS, Shen L, et al. Analysis of side effect profile of alopecia, nail changes, peripheral neuropathy, and dysgeusia in prostate cancer patients treated with docetaxel and cabazitaxel. Clin Genitourin Cancer. 2015;13(4):e205–8.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Akita University School of Medicine, Akita, Japan

    Shintaro Narita M.D. & Tomonori Habuchi M.D.

Authors
  1. Shintaro Narita M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tomonori Habuchi M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shintaro Narita M.D. .

Editor information

Editors and Affiliations

  1. Department of Urology, Tohoku University School of Medicine, Sendai, Japan

    Yoichi Arai

  2. Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan

    Osamu Ogawa

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Narita, S., Habuchi, T. (2018). Intermittent Chemotherapy with Docetaxel for Metastatic Castration-Resistant Prostate Cancer. In: Arai, Y., Ogawa, O. (eds) Hormone Therapy and Castration Resistance of Prostate Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-10-7013-6_36

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-7013-6_36

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-7012-9

  • Online ISBN: 978-981-10-7013-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation